Brian B Berger MD board certified
Retinal Disease, Uveitis
president, Retina Research Center
Join to view full profile
9707 Anderson Mill Rd Ste 100Austin, TX 78750
Phone+1 512-279-1251
Fax+1 512-454-5853
Dr. Berger is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Medical College of Wisconsin Affiliated HospitalsResidency, Ophthalmology, 1979 - 1980
University of Illinois College of Medicine at ChicagoResidency, Ophthalmology, 1976 - 1979
Valleywise HealthInternship, Transitional Year, 1975 - 1976
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1975
Certifications & Licensure
TX State Medical License 1981 - 2026
IL State Medical License 1976 - 2014
WI State Medical License 1979 - 1981
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification IntelleChart, MDIntelleSys, A Nextech Company, 2016
- Top Doctors:SE Texas Castle Connolly, 2013
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)
- Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control
- A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Publications & Presentations
PubMed
- 1 citationsCANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy.Beatriz G Armendariz, Ulrich F O Luhman, Brian Berger, Jules Hernandez-Sanchez, Katrijn Bogman
Ophthalmology Science. 2024-11-08 - 35 citationsArchway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.Carl Regillo, Brian Berger, Logan Brooks, W Lloyd Clark, Robert Mittra
Ophthalmology. 2023-07-01 - 3 citationsImplantation Site of a Port Delivery System With Ranibizumab: Anterior Segment Optical Coherence Tomography Evaluation.Connor J Ericksen, Cory A Christensen, Brian Berger, Shamika Gune, Jared S Nielsen
Journal of Vitreoretinal Diseases. 2022-08-04
Journal Articles
- A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular EdemaBrian Berger, Douglas Girgenti, Ronald A Schachar, Marla B Sultan, Investigative Ophthalmology and Visual Science
Press Mentions
Effect of Initial Management with Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients with Diabetic Macular Edema Involving the Center of the Macula and Good Visual AcuityMay 1st, 2019
Professional Memberships
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
